TPGS-based and S-thanatin functionalized nanorods for overcoming drug resistance in Klebsiella pneumonia.
Xiaojuan WangXiaoling XuShaojun ZhangNa ChenYunfeng SunKuifen MaDongsheng HongLu LiYong-Zhong DuXiaoyang LuSaiping JiangPublished in: Nature communications (2022)
Tigecycline is regarded as the last line of defense to combat multidrug-resistant Klebsiella pneumoniae. However, increasing utilization has led to rising drug resistance and treatment failure. Here, we design a D-alpha tocopheryl polyethylene glycol succinate-modified and S-thanatin peptide-functionalized nanorods based on calcium phosphate nanoparticles for tigecycline delivery and pneumonia therapy caused by tigecycline-resistant Klebsiella pneumoniae. After incubation with bacteria, the fabricated nanorods can enhance tigecycline accumulation in bacteria via the inhibitory effect on efflux pumps exerted by D-alpha tocopheryl polyethylene glycol succinate and the targeting capacity of S-thanatin to bacteria. The synergistic antibacterial capacity between S-thanatin and tigecycline further enhances the antibacterial activity of nanorods, thus overcoming the tigecycline resistance of Klebsiella pneumoniae. After intravenous injection, nanorods significantly reduces the counts of white blood cells and neutrophils, decreases bacterial colonies, and ameliorates neutrophil infiltration events, thereby largely increasing the survival rate of mice with pneumonia. These findings may provide a therapeutic strategy for infections caused by drug-resistant bacteria.
Keyphrases
- klebsiella pneumoniae
- multidrug resistant
- drug resistant
- acinetobacter baumannii
- gram negative
- reduced graphene oxide
- escherichia coli
- induced apoptosis
- quantum dots
- cancer therapy
- gold nanoparticles
- stem cells
- oxidative stress
- insulin resistance
- high resolution
- skeletal muscle
- intensive care unit
- pseudomonas aeruginosa
- high dose
- mesenchymal stem cells
- type diabetes
- high fat diet induced
- cystic fibrosis
- smoking cessation
- acute respiratory distress syndrome
- drug delivery